Biglycan Antikörper (C-Term)
-
- Target Alle Biglycan (BGN) Antikörper anzeigen
- Biglycan (BGN)
-
Bindungsspezifität
- C-Term
-
Reaktivität
- Human, Maus
-
Wirt
- Ziege
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser Biglycan Antikörper ist unkonjugiert
-
Applikation
- ELISA, Immunofluorescence (IF)
- Verwendungszweck
- Biglycan Preproprotein
- Sequenz
- DRLAIQFGNY KK
- Kreuzreaktivität
- Hund, Human, Maus, Ratte
- Aufreinigung
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
- Güteklasse
- Verified
- Immunogen
- Peptide with sequence C-DRLAIQFGNYKK, from the C Terminus of the protein sequence according to NP_001702.1.
- Isotyp
- IgG
- Top Product
- Discover our top product BGN Primärantikörper
-
-
- Applikationshinweise
- Peptide ELISA: antibody detection limit dilution 1:2000.
- Kommentare
-
Immunofluorescence: Expression of the protein seen in the Golgi of NIH3T3 and HepG2 cells. Recommended concentration: 10μg/ml.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.5 mg/mL
- Buffer
- Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Minimize freezing and thawing.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.
-
-
Arguments for an increasing differentiation towards fibrocartilaginous components in midportion Achilles tendinopathy." in: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, Vol. 21, Issue 6, pp. 1459-67, (2013) (PubMed).
: "
-
Arguments for an increasing differentiation towards fibrocartilaginous components in midportion Achilles tendinopathy." in: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, Vol. 21, Issue 6, pp. 1459-67, (2013) (PubMed).
-
- Target
- Biglycan (BGN)
- Andere Bezeichnung
- BGN (BGN Produkte)
- Synonyme
- DSPG1 antikoerper, PG-S1 antikoerper, PGI antikoerper, SLRR1A antikoerper, BG antikoerper, BSPG1 antikoerper, bgn antikoerper, zgc:91989 antikoerper, dspg1 antikoerper, pg-s1 antikoerper, slrr1a antikoerper, xbgn antikoerper, BGN antikoerper, zgc:77123 antikoerper, DKFZp468I2427 antikoerper, biglycan antikoerper, biglycan L homeolog antikoerper, biglycan a antikoerper, biglycan S homeolog antikoerper, biglycan b antikoerper, BGN antikoerper, Bgn antikoerper, bgn.L antikoerper, bgna antikoerper, bgn.S antikoerper, bgn antikoerper, bgnb antikoerper
- Hintergrund
- Biglycan Preproprotein, biglycan, BGN, DSPG1, PG-S1, PGI, SLRR1A , bone/cartilage proteoglycan-I, dermatan sulphate proteoglycan I, small leucine-rich protein 1A
- Gen-ID
- 633, 12111, 25181
- NCBI Accession
- NP_001702
- Pathways
- Glycosaminoglycan Metabolic Process
-